TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $700,556 | -42.9% | 78,362 | -1.9% | 0.04% | -37.1% |
| Q2 2023 | $1,226,388 | -28.7% | 79,843 | +4.4% | 0.07% | -28.6% |
| Q1 2023 | $1,720,440 | +7.3% | 76,498 | +0.4% | 0.10% | +6.5% |
| Q4 2022 | $1,602,654 | -16.4% | 76,208 | -2.1% | 0.09% | -17.1% |
| Q3 2022 | $1,918,000 | -22.4% | 77,837 | -23.7% | 0.11% | -6.7% |
| Q2 2022 | $2,471,000 | -3.7% | 101,991 | +2.4% | 0.12% | +16.7% |
| Q1 2022 | $2,566,000 | -14.0% | 99,563 | +3.5% | 0.10% | -3.8% |
| Q4 2021 | $2,985,000 | +12.7% | 96,176 | -11.9% | 0.11% | +8.2% |
| Q3 2021 | $2,648,000 | +69.9% | 109,206 | +2.2% | 0.10% | +78.2% |
| Q2 2021 | $1,559,000 | -44.2% | 106,827 | -4.5% | 0.06% | -39.6% |
| Q1 2021 | $2,794,000 | -8.4% | 111,900 | +0.0% | 0.09% | -15.0% |
| Q4 2020 | $3,049,000 | – | 111,864 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |